Question: Do we expect to run out of hepatitis medicine due to this pandemic?

Answer passage (source: CDC):
page_title: What to Know About Liver Disease and COVID-19
section_headers: Are shortages of hepatitis B or hepatitis C medicine expected?
section_content: No drug shortages or anticipated problems with medicine used to treat
hepatitis B or hepatitis C have been identified to date.
The U.S. Food and Drug Administration (FDA) is closely monitoring the drug
supply chain because the COVID-19 outbreak has the potential to disrupt the
supply of medical and pharmaceutical products in the United States.
Learn more about the FDA’s response to COVID-19external
icon and information on drug shortagesexternal
icon.

Reviewer feedback on this answer:
Provides a clear answer about whether hepatitis medication will continue to be available.
The response was not linked to the pandemic

Reviewer ratings:
Excellent
Acceptable

Answer passage (source: CDC):
page_title: Clinical Questions about COVID-19: Questions and Answers
section_headers: Patients with Liver Disease
Should hepatitis A and hepatitis B vaccines continue to be administered to adults at risk for hepatitis A or hepatitis B?
section_content: Yes. Continue to administer these vaccines if an in-person visit must be
scheduled for some other purpose and the clinical preventive service can be
delivered during that visit with no additional risk; or an individual patient
and their clinician believe that there is a compelling need to receive the
service based on an assessment that the potential benefit outweighs the risk
of exposure to SARS-CoV-2 virus. For more information see Delivery of Adult
Clinical Preventive Services, Including
Immunizations.

Reviewer feedback on this answer:
Discusses vaccines, not potential mediation shortages like question asks.
still did not mention exactly why there would be a direct effect of the pandemic on Hepatitis vaccine

Reviewer ratings:
Bad
Acceptable

Answer passage (source: CDC):
page_title: Clinical Questions about COVID-19: Questions and Answers
section_headers: Patients with Liver Disease
During the COVID-19 pandemic, should high-risk populations continue to be vaccinated for hepatitis A in response to the ongoing hepatitis A outbreaks?
section_content: Yes. People susceptible to hepatitis A virus (HAV) infection during the
current hepatitis A outbreaks should receive the hepatitis A vaccine when
possible. This includes:

people who use drugs (injection or non-injection)
people experiencing unstable housing or homelessness
men who have sex with men (MSM)
people who are or were recently incarcerated
people with chronic liver disease (including cirrhosis, hepatitis B, or hepatitis C) and living or working in areas where the hepatitis A outbreaks are ongoing

Vaccination in settings such as jails, other correctional facilities, and
homeless shelters should continue if already previously planned and organized
in a way that would adhere to infection control practices and where relevant
social distancing standards can be maintained. However, efforts should be made
to vaccinate people in non-congregate settings that allow for social
distancing. Whenever possible, vaccination efforts in non-congregate settings
should continue for people at highest risk of acquiring HAV infection or
developing serious complications from HAV infection, if social distancing
standards can be maintained.

Reviewer feedback on this answer:
Discusses hepatitis in the context of the coronavirus epidemic, but doesn't address medication shortages.
it should have stated how the pandemic could possibly affect the demand of hepatitis vaccine

Reviewer ratings:
Bad
Bad